You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁威生物(688062.SH):預計2021年度淨虧損6.66億元-7.82億元
格隆匯 01-25 18:13

格隆匯1月25日丨邁威生物(688062.SH)公佈2021年年度業績預吿,公司預計2021年年度實現歸屬於母公司所有者的淨利潤-6.66億元到-7.82億元,相比上期虧損增加2393.68萬元到1.398億元。

公司預計2021年年度實現歸屬於母公司所有者扣除非經常性損益後的淨利潤-6.64億元到-7.798億元,相比上期減少虧損1525.90萬元到增加虧損1.00億元。

業績變化的主要原因:

(一)報吿期內,公司所有在研產品均處於研發階段,尚未開展商業化銷售,公司產品尚未實現銷售收入。報吿期內,公司主營業務收入主要為技術服務收入。

(二)公司持續投入大量資金用於在研品種的臨牀前研究及臨牀試驗,報吿期內,公司多項在研品種新推進至臨牀研究階段導致公司研發費用金額較高。2021年12月,在研品種管線中部分品種進度提前於預期,因此原計劃2022年一季度發生的研發費用亦提前至報吿期內。

(三)報吿期內,非經常性損益主要包括股權激勵的取消而加速行權確認的股份支付費用。上年同期未發生一次性股權激勵計提或加速行權確認的股份支付費用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account